See today's BioWorld
To read the full story, subscribe or sign in.

Moonlake stock drops as phase II data in psoriatic arthritis is posted

Nov. 6, 2023
By Lee Landenberger
Top-line results from Moonlake Immunotherapeutics AG’s phase II study of sonelokimab treating active psoriatic arthritis encouraged the company but discouraged investors.
BioWorld Clinical Immune